drugset / Trial / NCT06489951

Efficacy and Mechanism of High-Dose Vitamin D Supplementation in Pediatric OAB-Dry: A Randomized Clinical Trial Integrating Urinary Myelin Basic Protein as a Theranostic Biomarker

NCT06489951

RandomizedParallel-groupDouble-blindTreatment

Summary

The aim of this study is to give children with dry OAB: (1) Standard behavioral therapy combined with classical anticholinergic drugs (Solinaxine), or (2) standard behavioral therapy combined with short-term high-dose exogenous vitamin D supplementation are used to compare the outcomes of lower urinary tract symptoms in children with dry OAB during follow-up. To provide more robust supporting evidence for the broader promotion of short-term high-dose exogenous vitamin D supplements in combination with standard behavioral therapy as an effective treatment for dry OAB treatment in children.

Timeline

Start
2024-12-28
Primary completion
2025-06-30
Completion
2025-07-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Solifenacin Small molecule 0.5 mg Oral
Subject Solifenacin Small molecule 5 mg Oral

Indications